⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562972 | 0.67 | — | — | |
| SCHEMBL11844833 | 0.61 | — | — | |
| SCHEMBL411877 | 0.61 | — | — | |
| SCHEMBL2938390 | 0.58 | — | — | |
| SCHEMBL23453889 | 0.50 | — | — | |
| SCHEMBL1316766 | 0.50 | — | — | |
| SCHEMBL25218393 | 0.50 | — | — | |
| SCHEMBL10415641 | 0.50 | — | — | |
| SCHEMBL6282335 | 0.50 | — | — | |
| SCHEMBL29491022 | 0.50 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117396074-A | Fungicidal compositions containing oxadiazole compounds | PI工业有限公司 | 2024-01-12 | — | — | CN | claimed |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | disclosed |
| US-20200138779-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2020-05-07 | — | — | US | disclosed |
| EP-3532049-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | Ticure Ltd. (IL) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018078624-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2018-05-03 | — | — | WO | disclosed |
| US-9302982-B2 | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use | GLYCON LLC (US) | 2016-04-05 | — | — | US | disclosed |
| US-20130203855-A1 | Pharmaceutical Dopamine Glycoconjugate Compositions and Methods of Their Preparation and Use | GLYCON LLC (US) | 2013-08-08 | — | — | US | disclosed |
| US-8252752-B2 | An amidation product of ribosyl or glucosyl saccharide and a dopamine or derivative (forms amide through amine and carboxylic group); useful for treating neurological diseases including Parkinson's | GLYCON LLC (US) | 2012-08-28 | — | — | US | disclosed |
| US-7629472-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-08 | — | — | US | disclosed |
| US-20080194802-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE | GLYCON LLC | 2008-08-14 | — | — | US | disclosed |
| US-7247732-B2 | Method for producing optically active compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20060229457-A1 | Method for producing optically active compound | YAMANO TORU | 2006-10-12 | — | — | US | disclosed |
| EP-1385857-A4 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | INTERNAT MEDICAL INNOVATIONS I (US) | 2006-09-06 | — | — | EP | disclosed |
| US-7084278-B2 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-08-01 | — | — | US | disclosed |
| US-20050250739-A1 | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use | GLYCON LLC | 2005-11-10 | — | — | US | disclosed |
| US-20050107433-A1 | Process for production of optically active compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | disclosed |
| EP-1489070-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1385857-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | International Medical Innovations, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6548484-B1 | An amidation product of ribosyl or glucosyl saccharide and a dopamine or derivative ( forms a amide through amine and carboxylic group); useful for treating neurological diseases including Parkinson's and related diseases | INTERNATIONAL MEDICAL INNOVATIONS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-2001079244-A1 | PHARMACEUTICAL DOPAMINE GLYCOCONJUGATE COMPOSITIONS AND METHODS OF THEIR PREPARATION | INTERNATIONAL MEDICAL INNOVATIONS, INC. (US) | 2001-10-25 | — | — | WO | disclosed |